vatalanib has been researched along with everolimus in 7 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | vatalanib (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Allegrini, PR; Boulay, A; Brueggen, J; Lane, HA; Littlewood-Evans, A; Maira, SM; Martiny-Baron, G; McSheehy, PM; O'Reilly, T; Schnell, CR; Sini, P; Wood, JM | 1 |
| Cejka, D; Fuereder, T; Hoeflmayer, D; Jaeger-Lansky, A; Koehrer, S; Preusser, M; Wacheck, V; Ying, L | 1 |
| Brueggen, J; Lane, HA; Littlewood-Evans, A; McSheehy, PM; O'Reilly, T; Schnell, C; Wood, JM | 1 |
| Armstrong, AJ; Bitting, RL; Creel, PA; George, DJ; Healy, P; Hurwitz, HI; Morris, K; Nixon, AB; Starr, MD; Turnbull, J; Wood, SY | 1 |
| Hirt, SW; Keil, L; Lehle, K; Schaub, AL; Schmid, C; von Suesskind-Schwendi, M | 1 |
| Adjei, AA; Croghan, GA; Dy, GK; Glockner, J; Hanson, LJ; Molina, JR; Qi, Y; Roos, MM; Tan, AD; Zhu, M | 1 |
2 trial(s) available for vatalanib and everolimus
| Article | Year |
|---|---|
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Phthalazines; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2014 |
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Humans; Male; Middle Aged; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2020 |
5 other study(ies) available for vatalanib and everolimus
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Everolimus; Female; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Rats; Rats, Inbred BN; Rats, Inbred WF; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Female; Mechanistic Target of Rapamycin Complex 1; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Models, Biological; Multiprotein Complexes; Neoplasm Metastasis; Phthalazines; Proteins; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Synergism of imatinib, vatalanib and everolimus in the prevention of chronic lung allograft rejection after lung transplantation (LTx) in rats.
Topics: Animals; Bronchiolitis Obliterans; Drug Synergism; Everolimus; Fibrosis; Graft Rejection; Imatinib Mesylate; Immunohistochemistry; Lung Transplantation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred F344; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; TOR Serine-Threonine Kinases; Transplantation, Homologous; Vascular Endothelial Growth Factor Receptor-2 | 2019 |